PAVM - PAVmed Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2100
-0.1500 (-11.03%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close1.3600
Open1.3700
Bid0.0000 x 3000
Ask1.4500 x 800
Day's Range1.1900 - 1.4899
52 Week Range1.1900 - 9.3100
Volume286,089
Avg. Volume69,163
Market Cap21.187M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7700
Earnings DateNov 30, 2017 - Dec 4, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • Business Wireyesterday

    PAVmed Updates Expected Key Dates for Previously Announced Rights Offering

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, previously announced on May 8, 2018 that the Company had filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018. PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company.

  • Business Wire2 days ago

    PAVmed Reports First Quarter 2018 Financial Results

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today reports financial results for the three months ended March 31, 2018 and provides a business update.

  • Business Wire6 days ago

    PAVmed Inc. to Hold Business Update Conference Call on May 30, 2018

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a conference call on Wednesday, May 30, 2018 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s Chief Financial Officer, will discuss first quarter 2018 financial results.

  • Business Wire9 days ago

    PAVmed Announces Adjustment to Series Z Warrant Exercise Price

    PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, announced today that its board of directors approved a reduction to the exercise price of its Series Z Warrants (CUSIP number 70387R122) (the “Series Z Warrants”) that trade under the symbol “PAVMZ” on the Nasdaq Capital Market from $3.00 per share to $1.60 per share. The effective date of the exercise price reduction will be June 1, 2018. PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company.

  • Business Wire10 days ago

    PAVmed and Case Western Reserve University Finalize Definitive Licensing Agreement for Groundbreaking EsoCheck Technology

    PAVmed Inc. (Nasdaq:PAVM, PAVMZ), a highly differentiated, multi-product medical device company, today announced it has finalized a definitive licensing agreement with Case Western Reserve University to develop and commercialize its groundbreaking EsoCheck technology. EsoCheck is a rapid office-based alternative to diagnostic endoscopy that combines a non-invasive cell sampling device with a DNA biomarker test. Together these have been shown to be highly accurate in detecting Barrett’s Esophagus, the primary precursor to the most common and lethal form of esophageal cancer caused by Gastroesophageal Reflux Disease (GERD), commonly known as heart burn or acid reflux.

  • Business Wire16 days ago

    PAVmed Sets Record Date for Previously Announced Rights Offering

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company has filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018. Under the proposed Rights Offering, the Company will distribute non-transferable subscription rights to purchase a new unit (the “Unit”) for each share of Common Stock outstanding, at a subscription price per Unit of $2.25, to its stockholders on the record date.

  • Business Wirelast month

    PAVmed Signs Letter of Intent with Case Western Reserve University to Commercialize Groundbreaking EsoCheck Technology

    PAVmed Inc. , a highly differentiated, multi-product medical device company, today announced that it has signed a letter of intent with Case Western Reserve University to commercialize its groundbreaking EsoCheck technology.

  • Business Wirelast month

    PAVmed Reports Fourth Quarter and Full Year 2017 Financial Results

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today reports financial results for the three and 12 months ended December 31, 2017 and provides a business update.

  • Business Wire2 months ago

    PAVmed Announces Final Results of Offer to Exchange Series W Warrants for Series Z Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the final results of its previously disclosed offer to exchange each of its Series W Warrants for 0.5 Series Z Warrants .

  • Business Wire2 months ago

    PAVmed Inc. to Hold Business Update Conference Call on April 11, 2018

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that the Company will host a conference call on Wednesday, April 11, 2018 at 4:30 p.m.

  • Business Wire2 months ago

    PAVmed Announces Preliminary Results of Offer to Exchange Series W Warrants for Series Z Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the preliminary results of its previously disclosed offer to exchange each of its Series W Warrants for 0.5 Series Z Warrants .

  • ACCESSWIRE2 months ago

    Pavmed to Present at The Microcap Conference

    NEW YORK, NY / ACCESSWIRE / April 2, 2018 / PAVmed Inc. (NASDAQ: PAVM)(NASDAQ: PAVMW) (the ''Company''), a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, ...

  • Business Wire2 months ago

    PAVmed Announces Extension of Offer to Exchange Series W Warrants for Series Z Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that its previously disclosed offer to exchange Series W Warrants for Series Z Warrants has been extended, in accordance with applicable rules and regulations governing tender offers, until 5:00 P.M., Eastern Time, on April 2, 2018, unless further extended or terminated.

  • Business Wire2 months ago

    PAVmed to Present at the 28th Annual Oppenheimer Healthcare Conference

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m.

  • Who Are The Major Shareholders In PAVmed Inc (NASDAQ:PAVM)?
    Simply Wall St.3 months ago

    Who Are The Major Shareholders In PAVmed Inc (NASDAQ:PAVM)?

    Today, I will be analyzing PAVmed Inc’s (NASDAQ:PAVM) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its share performanceRead More...

  • Business Wire3 months ago

    PAVmed Initiates Offer to Exchange Outstanding Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the filing of a warrant exchange offer with the U.S.

  • Is PAVmed Inc (NASDAQ:PAVM) Overpaying Its CEO?
    Simply Wall St.3 months ago

    Is PAVmed Inc (NASDAQ:PAVM) Overpaying Its CEO?

    Lishan Aklog took the reins as CEO of PAVmed Inc’s (NASDAQ:PAVM) and grew market cap to US$27.87M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • Business Wire3 months ago

    PAVmed to Offer Opportunity to Exchange Outstanding Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced it intends to file exchange offer materials providing the holders of the Company’s outstanding Series W Warrants with the opportunity to exchange 2 W Warrants for 1 Series Z Warrant .

  • Business Wire3 months ago

    PAVmed Announces Completion of Offer to Exercise Series W Warrants at a Temporarily Reduced Price

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the completion of its previously announced offer to exercise its publicly-traded warrants at a temporarily reduced exercise price of $2.00 per share.

  • Business Wire4 months ago

    PAVmed Announces Closing of Over-Allotment Option with Respect to Firm Commitment Common Stock Offering

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that it has completed the sale of 234,540 shares of common stock, $0.001 par value per share , in connection with the partial exercise of the over-allotment option granted to the underwriter in its previously announced public offering of 2,415,278 shares of Common Stock .

  • ACCESSWIRE4 months ago

    Dawson James Securities Announces the Closing of Firm Commitment Underwritten Public Offering for PAVmed Inc.

    BOCA RATON, FL / ACCESSWIRE / January 23, 2018 / Dawson James Securities, Inc. in conjunction with PAVMed, Inc. (NASDAQ: PAVM) announced the closing today of a firm commitment public offering of 2,415,278 ...

  • Business Wire4 months ago

    PAVmed Announces Closing of Firm Commitment Common Stock Offering

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the closing of its previously announced underwritten public offering of 2,415,278 shares of its common stock at a public offering price of $1.80 per share.

  • Business Wire4 months ago

    PAVmed Announces Pricing of Firm Commitment Common Stock Offering

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the pricing of its previously announced underwritten public offering of 2,415,278 shares of its common stock at a price to the public of $1.80 per share.

  • Business Wire4 months ago

    PAVmed Announces Firm Commitment Public Offering of Common Stock

    PAVmed Inc. ) , a highly differentiated, multiproduct medical device company, today announced that it intends to offer shares of common stock in an underwritten public offering.

  • Business Wire4 months ago

    PAVmed Sets Terms of Previously Announced Rights Offering

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that the Company has set the terms of its previously announced rights offering .